Spotlight On... San Diego engineers develop biosensor implant for real-time detection of DNA mutation; Elekta will distribute Kobold Medical's brachytherapy devices in the U.S.; Viveve Medical prices $14 million IPO; and more...

Engineers at the University of California at San Diego have developed an electrical graphene chip to detect mutations in DNA. It could be the basis of a biosensor chip that can be implanted in the body to offer detection of specific DNA mutations--that would transmit the data to a mobile device in real-time. But a lot of work has to be done first to understand what minute alterations in DNA actually mean when it comes to pathology. "We are at the forefront of developing a fast and inexpensive digital method to detect gene mutations at high resolution--on the scale of a single nucleotide change in a nucleic acid sequence," said Ratnesh Lal, professor of bioengineering, mechanical engineering and materials science in the Jacobs School of Engineering at UCSD, in a statement. This work could eventually add up to a real-time liquid biopsy implant. More

> Elekta has signed on to distribute Kobold Medical's brachytherapy applicators in the U.S. Release

> Viveve Medical raised $14 million in its IPO. The company, which is commercializing a noninvasive medical system to treat vaginal laxity will trade on the Nasdaq under the symbol VIVE. Release

> Geisinger Health Plan, which covers more than 500,000 people in Delaware, Maine, New Jersey, Pennsylvania and West Virginia announced that it will cover SI-Bone's iFuse Implant System for SI joint fusion. Release

Suggested Articles

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.

President Emmanuel Ligner talks about finalizing a multibillion-dollar deal while adjusting and responding to the global COVID-19 crisis.